Octave Specialty Group 과거 순이익 실적
과거 기준 점검 0/6
Octave Specialty Group 의 수입은 연평균 -16.5%의 비율로 감소해 온 반면, Insurance 산업은 연평균 14.6%의 비율로 증가했습니다. 매출은 연평균 1.2%의 비율로 감소해 왔습니다.
핵심 정보
-16.46%
순이익 성장률
-16.14%
주당순이익(EPS) 성장률
| Insurance 산업 성장률 | 8.02% |
| 매출 성장률 | -1.15% |
| 자기자본이익률 | -8.18% |
| 순이익률 | -32.69% |
| 최근 순이익 업데이트 | 31 Mar 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • May 13
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, citing updated assumptions that include a slightly lower discount rate, adjusted revenue growth expectations of 15.54%, a profit margin estimate of 10.93%, and a projected future P/E of 12.26x. What's in the News From October 1, 2025 to December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares for US$27.34 million, representing 6.73% of its shares.내러티브 업데이트 • Apr 22
OSG: Completed Buybacks Will Tighten Float And Support Future Upside Potential
Analysts have kept their $12.00 price target for Octave Specialty Group unchanged, noting only slight adjustments to underlying assumptions such as discount rate, revenue growth, profit margin, and future P/E, which they view as offsetting each other overall. What's in the News Between October 1, 2025 and December 31, 2025, Octave Specialty Group repurchased 3,142,554 shares, representing 6.73% of its shares, for $27.34 million under its existing buyback program (Key Developments).내러티브 업데이트 • Apr 07
OSG: Share Repurchases Will Tighten Float And Support Future Upside Potential
Analysts now maintain their price target for Octave Specialty Group at $12.00, citing similar fair value and margin assumptions, with only modest adjustments to revenue growth, the discount rate, and future P/E inputs. What's in the News Completed share repurchase of 4,371,886 shares, representing 9.33% of outstanding shares, for a total of $42.45 million under the buyback announced on November 12, 2024 (Key Developments).내러티브 업데이트 • Mar 23
OSG: Share Repurchases Will Support Future Upside Potential
Analysts now hold their price target for Octave Specialty Group at $12.00, reflecting slightly updated assumptions for revenue growth, profit margins, discount rate, and future P/E that fine tune rather than overhaul their prior view. What's in the News Completed share repurchase program with a total of 4,371,886 shares bought back for $42.45 million, representing 9.33% of shares under the buyback announced on November 12, 2024 (Key Developments).내러티브 업데이트 • Mar 09
OSG: Share Repurchases And Auditor Shift Will Support Future Upside Potential
Analysts have reduced their price target on Octave Specialty Group from $15.00 to $12.00, reflecting updated assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News Completed share repurchase of 4,371,886 shares in total, representing 9.33% of shares, for $41.69 million under the buyback announced on November 12, 2024.내러티브 업데이트 • Feb 22
OSG: Auditor Transition And Execution Will Support Future Upside Potential
Analysts have adjusted their price target on Octave Specialty Group to $15.00. This change reflects updated assumptions around slightly higher projected revenue growth, a modestly stronger profit margin, and a lower future P/E multiple.내러티브 업데이트 • Feb 07
OSG: ArmadaCare Execution And Organic Expansion Will Support Future Upside Potential
Analysts have raised their price target on Octave Specialty Group to $15 from $10, citing updated models that incorporate recent earnings, higher assumed organic growth, and the impact of the ArmadaCare deal. Analyst Commentary While the new US$15 price target signals higher modeled value for Octave Specialty Group, not all of the commentary behind the scenes is purely optimistic.내러티브 업데이트 • Jan 24
OSG: Higher Growth Assumptions And ArmadaCare Integration Will Drive Future Upside
Narrative Update Analysts have lifted their price target on Octave Specialty Group to US$15 from US$10, citing refreshed models that factor in higher assumed organic growth, the ArmadaCare acquisition and recent quarterly performance. Analyst Commentary While the higher US$15 target reflects more constructive modeling around organic growth and the ArmadaCare acquisition, not all commentary skews optimistic.
내러티브 업데이트 • Jan 09
OSG: Earnings Beat And ArmadaCare Integration Will Support Long-Term Share Gains
Analysts have raised their price target on Octave Specialty Group by $5 to $15, citing updated models that incorporate Q3 earnings, revised assumptions for organic growth, and the expected impact of the ArmadaCare transaction. Analyst Commentary Bullish Takeaways Bullish analysts point to the updated Q3 earnings model as support for the new US$15 price target, arguing that current valuation better reflects Octave Specialty Group's recent financial results.내러티브 업데이트 • Dec 25
OSG: Earnings Beat And Deals Will Drive Long-Term Shareholder Upside
Analysts raised their price target for Octave Specialty Group by $5, increasing it to $15 from $10. They cited updated models that reflect stronger assumed organic growth following an earnings beat and recent strategic transactions, which they believe support a path to sustained elevated expansion.내러티브 업데이트 • Dec 11
OSG: Q3 Earnings Beat Will Support Long-Term Shareholder Value Expansion
Analysts raised their price target on Octave Specialty Group to $15 from $10, citing updated models that reflect stronger than expected Q3 performance, higher assumed organic growth, and incremental upside from recent strategic deals. Analyst Commentary Analysts note that the revised price target for Octave Specialty Group is grounded in tangible improvements to the company’s growth profile, as well as rising confidence in management’s ability to execute on recent strategic initiatives.내러티브 업데이트 • Nov 27
OSG: Sustained Organic Expansion Will Drive Long-Term Shareholder Value
Analysts have raised their price target for Octave Specialty Group, increasing it by $5 to reflect stronger than expected organic growth and recent strategic acquisitions. Analyst Commentary Following the recent price target increase, analysts have provided additional context regarding their views on Octave Specialty Group's prospects.내러티브 업데이트 • Nov 13
AMBC: Revenue Momentum and Armada Acquisition Will Drive Further Share Upside
Analysts have raised their price target for Octave Specialty Group from $14.67 to $16.33. They cite stronger projected revenue growth and improved profitability metrics in their updated outlook.Seeking Alpha • Oct 03
Ambac: Surprise Acquisition Changes Outlook (Rating Downgrade)
Summary Ambac is downgraded to Hold following the surprise $250M ArmadaCare acquisition after selling its legacy guarantee business. The new deal adds product diversification and potential growth, but reintroduces debt and increases risk to the balance sheet. Management maintains 2028 adjusted EBITDA guidance at $80M–$90M, despite the significant size of the ArmadaCare acquisition. I recommend waiting for a lower entry price below $7 or more clarity in Q3 results before considering AMBC a Buy again. Read the full article on Seeking Alpha새로운 내러티브 • Jul 20
US Infrastructure Spending And Automation Will Unlock Insurance Potential
Diversification into specialty insurance and tech-driven operations is improving revenue stability, earnings quality, and operational efficiency.Seeking Alpha • Mar 01
Ambac: Despite EPS Miss, It's A Growth Company
Summary Ambac Financial Group saw a stock decline after an earnings miss for Q4. Such a sell-off overlooks the fundamental improvements: profitable underwriting and the build-out of a higher-ROE distribution platform. The sale of the legacy business remains to be approved by Wisconsin, creating a thorn in AMBC's side for the moment. Management, however, was eager about the growth ahead; the current price is a small P/E for earnings in just a few years. Read the full article on Seeking AlphaSeeking Alpha • Dec 27
Ambac Financial: Don't Get Lost In The Weeds; It's Working
Summary Ambac Financial Group has shifted from guarantee insurance to specialty property-casualty insurance and distribution. Despite a drop in tangible book value per share, the sale of the legacy business and recent acquisitions are expected to improve financials and boost earnings. Ambac Financial faces risks from recent hurricanes and potential delays in the legacy business sale approval, but overall outlook remains positive. I maintain a Buy rating on AMBC stock, believing Ambac's turnaround strategy will lead to better capitalization and improved earnings, offering a favorable risk-reward asymmetry. Read the full article on Seeking AlphaSeeking Alpha • Jul 30
Ambac Financial: Unbundling The Recent Sale And The New Acquisition
Summary Ambac sold its Financial Guarantee business to Oaktree at a disappointing valuation, causing a 20% drop in stock price. The company reinvested proceeds into acquiring a majority stake in Beat Capital Partners for $280 million at a generous valuation, raising concerns among investors. Despite the negative stock reaction, a new valuation framework suggests a fair value per share of around $15, indicating a 20% upside potential. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Ambac: Finally Shaking Off The Great Financial Crisis
Summary Ambac Financial Group has undergone a turnaround after the 2008 Financial Crisis, improving its financial position and evolving its business model. The company's balance sheet appears healthy and able to meet upcoming obligations, with a new focus on specialty property-casualty insurance. AMBC is positioning itself to underwrite its products through a technology-driven MGA model, aiming to take advantage of the growing US market with attractive loss ratios. Yet, investors should remember that the discount exists for a reason, given how a recession could particularly affect a company like this. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
Ambac: Releasable Liquidity And SOTP Analysis Reveals Upside Potential
Summary Ambac is a complex company with a financial guarantees business and a new specialty P&C insurance business. We run a comparison with MBIA to compute releasable liquidity from the FG business that may be paid out as a special dividend. Ambac may benefit from a liquidity release or a sale, but the bulk of its value lies in its new businesses. Read the full article on Seeking AlphaSeeking Alpha • Sep 24
Ambac Financial Group Inc: Debt Trap Disguised As Value Opportunity
Summary Ambac Financial Group Inc is trading at low multiples but has a significant amount of debt that is impacting its expansion capacities. AMBC operates through two divisions, Everspan and Cirrata, and presents itself as an opportunity in the growing specialty coverage market. The company's high debt levels and inconsistent bottom line make it a risky investment, and the share price is expected to decline further. Read the full article on Seeking AlphaSeeking Alpha • Jun 14
Ambac Remains Discounted By An Apprehensive Market
Summary Ambac has seen significant price appreciation since the announced settlement with Bank of America and Nomura Holdings. Alongside aggressive growth from Cirrata, shareholders can expect effective organic and inorganic growth from Ambac. Despite these factors, Ambac still trades at a 23% undervaluation, leading me to rate the company a 'buy'. Read the full article on Seeking AlphaSeeking Alpha • Jan 03
Ambac settles with Nomura, closing financial crisis-era RMBS lawsuits
Ambac Financial Group (NYSE:AMBC) said Tuesday its Assurance Corporation subsidiary (AAC) entered into a settlement agreement with Nomura (NYSE:NMR) that will give AAC $140M. The settlement brings to an end all of Ambac's (AMBC) legacy residential mortgage-backed securities representation and warranty litigation that arose from the 2008 financial crisis. In October, Bank of America (BAC) agreed to pay Ambac $1.8B to settle litigation related to mortgage company Countrywide's collapse during the crisis. The settlement exceeds the amount of recovery recorded on Ambac's (AMBC) Q3 2022 GAAP financial statements attributed to the Nomura (NMR) litigation. As a result, the company will record a gain of ~$43M in its Q4 financial statement. Last month, Street Insider reported that Assured Guaranty (AGO) and Ambac Financial (AMBC) had made bids for rival MBIA (MBI).분석 기사 • May 12
Just In: One Analyst Has Become A Lot More Bullish On Ambac Financial Group, Inc.'s (NYSE:AMBC) Earnings
Celebrations may be in order for Ambac Financial Group, Inc. ( NYSE:AMBC ) shareholders, with the covering analyst...매출 및 비용 세부 내역
매출 및 비용 세부 내역
Octave Specialty Group가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 31 Mar 26 | 293 | -96 | 179 | 0 |
| 31 Dec 25 | 251 | -117 | 166 | 0 |
| 30 Sep 25 | 254 | -106 | 183 | 0 |
| 30 Jun 25 | 258 | -94 | 165 | 0 |
| 31 Mar 25 | 254 | -87 | 141 | 0 |
| 31 Dec 24 | 241 | -65 | 122 | 0 |
| 30 Sep 24 | 105 | -78 | 1 | 0 |
| 30 Jun 24 | 104 | 8 | 40 | 0 |
| 31 Mar 24 | 113 | 10 | 56 | 0 |
| 31 Dec 23 | 125 | -20 | 67 | 0 |
| 30 Sep 23 | 325 | 197 | 173 | 0 |
| 30 Jun 23 | 320 | 471 | 138 | 0 |
| 31 Mar 23 | 273 | 489 | 144 | 0 |
| 31 Dec 22 | 54 | -33 | 56 | 0 |
| 30 Sep 22 | 234 | 327 | 107 | 0 |
| 30 Jun 22 | 216 | 4 | 108 | 0 |
| 31 Mar 22 | 258 | -31 | 102 | 0 |
| 31 Dec 21 | 249 | -29 | 111 | 0 |
| 30 Sep 21 | 245 | -23 | 119 | 0 |
| 30 Jun 21 | 254 | -148 | 110 | 0 |
| 31 Mar 21 | 275 | -153 | 102 | 0 |
| 31 Dec 20 | 156 | -437 | 92 | 0 |
| 30 Sep 20 | 175 | -533 | 90 | 0 |
| 30 Jun 20 | 195 | -359 | 93 | 0 |
| 31 Mar 20 | 217 | -453 | 102 | 0 |
| 31 Dec 19 | 362 | -216 | 103 | 0 |
| 30 Sep 19 | 337 | -126 | 101 | 0 |
| 30 Jun 19 | 393 | -296 | 104 | 0 |
| 31 Mar 19 | 444 | -163 | 101 | 0 |
| 31 Dec 18 | 506 | 186 | 112 | 0 |
| 30 Sep 18 | 629 | 187 | 120 | 0 |
| 30 Jun 18 | 629 | 100 | 126 | 0 |
| 31 Mar 18 | 613 | 102 | 131 | 0 |
| 31 Dec 17 | 567 | -329 | 122 | 0 |
| 30 Sep 17 | 551 | -404 | 130 | 0 |
| 30 Jun 17 | 577 | -112 | 117 | 0 |
| 31 Mar 17 | 576 | -60 | 114 | 0 |
| 31 Dec 16 | 552 | 75 | 114 | 0 |
| 30 Sep 16 | 542 | 557 | 105 | 0 |
| 30 Jun 16 | 532 | 64 | 108 | 0 |
| 31 Mar 16 | 584 | 288 | 106 | 0 |
| 31 Dec 15 | 688 | 493 | 103 | 0 |
| 30 Sep 15 | 662 | 560 | 102 | 0 |
| 30 Jun 15 | 685 | 1,033 | 102 | 0 |
양질의 수익: OSG 은(는) 현재 수익성이 없습니다.
이익 마진 증가: OSG는 현재 수익성이 없습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: OSG은 수익성이 없으며 지난 5년 동안 손실이 연평균 16.5% 증가했습니다.
성장 가속화: 현재 수익성이 없어 지난 1년간 OSG의 수익 성장률을 5년 평균과 비교할 수 없습니다.
수익 대 산업: OSG은 수익성이 없어 지난 해 수익 성장률을 Insurance 업계(36.5%)와 비교하기 어렵습니다.
자기자본이익률
높은 ROE: OSG는 현재 수익성이 없으므로 자본 수익률이 음수(-8.18%)입니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/31 23:04 |
| 종가 | 2026/05/29 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Octave Specialty Group, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Giuliano Anderes Bologna | BTIG |
| Mary Kane | Citigroup Inc |
| Giuliano Anderes Bologna | Compass Point Research & Trading, LLC |